When will the MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER patents expire, and when will generic MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun Medical	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	meropenem	POWDER;INTRAVENOUS	202106-002	Apr 30, 2015		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
B Braun Medical	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	meropenem	POWDER;INTRAVENOUS	202106-001	Apr 30, 2015		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 31, 2026

Meropenem and Sodium Chloride in the DUPLEX container is a hospital injectable antibiotic product that combines generic meropenem with 0.9% sodium chloride in a dual-chamber delivery system. Its commercial value is driven by hospital procurement, supply reliability, antimicrobial-resistance demand, manufacturing capacity, and contract pricing rather than by patent exclusivity.

The investment profile is defensive but low-growth. The product can support recurring institutional demand, yet generic competition, price compression, dependence on hospital contracts, and limited differentiation constrain pricing power. The DUPLEX presentation can improve handling and preparation efficiency, but it does not create the same exclusivity profile as a novel drug or biologic delivery technology.

What is Meropenem and Sodium Chloride in the DUPLEX Container?

Meropenem is a carbapenem antibacterial administered intravenously for serious bacterial infections. The product combines meropenem powder with sodium chloride injection in a dual-chamber container. The chambers are activated before administration, allowing reconstitution and dilution within the container.

Typical presentations include:

Product characteristic	Description
Active ingredient	Meropenem
Diluent	0.9% sodium chloride injection
Dosage form	Intravenous powder for solution
Delivery system	DUPLEX dual-chamber container
Therapeutic category	Carbapenem antibacterial
Primary customers	Hospitals, health systems, government purchasers, group purchasing organizations
Regulatory pathway	Generic injectable drug, generally approved through an ANDA or equivalent abbreviated pathway
Main competitors	Meropenem vials, premixed meropenem products, other carbapenems, alternative broad-spectrum antibiotics

The product is used in hospital settings where rapid preparation, sterile handling, and dependable availability are important. It is not a retail pharmacy product and generally does not have a consumer-driven brand franchise.

What are the FDA regulatory and Orange Book characteristics?

Meropenem products are regulated as prescription injectable drugs. The relevant regulatory issues are manufacturing quality, sterility, container integrity, stability, reconstitution instructions, labeling, and bioequivalence or pharmaceutical equivalence requirements applicable to the approved product.

FDA approval of a generic injectable product does not necessarily create a new period of market exclusivity. The underlying meropenem molecule is an established generic active ingredient, and the commercial competition is primarily among approved manufacturers and suppliers.

What is the Orange Book status of meropenem products?

The FDA Orange Book identifies approved drug products and, where applicable, patents and exclusivity associated with listed reference products. For a mature generic meropenem presentation, the principal investment conclusion is that the active ingredient does not provide meaningful current patent protection.

The relevant distinction is between:

The original meropenem molecule and its historical patents.
Generic meropenem vial products.
The DUPLEX container and related formulation or packaging claims.
Manufacturing, stability, and container-closure technology.

A product may be commercially protected by supply contracts, manufacturing know-how, customer qualification, or regulatory complexity even when it lacks enforceable composition-of-matter exclusivity.

When does meropenem lose exclusivity?

Meropenem’s core exclusivity expired years ago. Generic competition has been established for the active ingredient, and the principal patent risk is not loss of a current molecule patent.

The relevant commercial timeline is:

Period	Market condition
Original branded period	Meropenem was marketed as Merrem and protected by historical patent and regulatory exclusivity
Generic entry period	Multiple generic manufacturers entered after loss of core exclusivity
Current market	Competition is based on manufacturing reliability, price, dosage presentation, and hospital contracting
Future outlook	Additional generic or premixed presentations can increase price pressure

The DUPLEX format may be covered by product-specific patents, container patents, process patents, or contractual rights, but those rights generally have narrower economic scope than a composition-of-matter patent. A competing manufacturer can often enter with a conventional vial even if it cannot duplicate the exact container.

What patents protect Meropenem and Sodium Chloride in the DUPLEX container?

The commercial patent estate is likely to divide into four categories:

Patent category	Economic relevance
Meropenem molecule patents	Largely expired and no longer a material barrier to generic entry
Formulation patents	May address concentration, pH, stability, reconstitution, or excipient selection
Container patents	May cover dual-chamber construction, seals, ports, or activation mechanisms
Manufacturing patents	May cover filling, sterilization, lyophilization, packaging, or stability processes

For investment purposes, the key point is that a container patent does not necessarily block all meropenem competition. A rival can use a conventional vial, another premix system, or a different dual-chamber package.

What formulations are protected?

The principal technical protection areas may include:

Meropenem stability after reconstitution.
Compatibility with sodium chloride injection.
Lyophilized powder characteristics.
Moisture protection.
Container-closure integrity.
Reconstitution time.
Extended in-use stability.
Sterilization and filling processes.
Compatibility of the drug chamber with the diluent chamber.

These claims can create regulatory and manufacturing friction. They are less likely to support durable price premiums unless the product has a meaningful supply or workflow advantage.

How strong is the patent estate?

The patent estate is weak for the active ingredient and potentially moderate for specialized packaging or manufacturing technology.

Dimension	Assessment
Composition-of-matter protection	Weak or expired
Method-of-use protection	Weak for routine antibacterial uses
Formulation protection	Potentially narrow
Container protection	Potentially meaningful but design-around risk exists
Manufacturing protection	Relevant to quality and scale, not necessarily market exclusivity
Generic entry barrier	Moderate for sterile injectable production
Long-term pricing power	Low
Litigation leverage	Limited unless a live container or formulation patent is asserted

The most important barrier is operational. Sterile injectable manufacturing requires validated facilities, reliable active pharmaceutical ingredient supply, quality systems, and regulatory compliance. Those requirements can reduce the number of dependable suppliers, but they do not eliminate competitive entry.

Which companies compete with the DUPLEX product?

Competition comes from both direct and indirect sources.

Direct meropenem competitors

Direct competitors include manufacturers of:

Meropenem for injection in single-dose vials.
Meropenem in premixed containers.
Meropenem products supplied through hospital purchasing contracts.
Authorized generic or branded equivalents.

The relevant competitive set may include Baxter, Pfizer or Hospira, Fresenius Kabi, Sandoz, Hikma, Eugia, Dr. Reddy’s, Aurobindo, and other approved generic injectable manufacturers, depending on the specific strength, presentation, and market.

Therapeutic competitors

Hospitals may substitute other broad-spectrum antibiotics based on pathogen susceptibility, infection site, renal function, formulary policy, and antimicrobial stewardship protocols. Alternatives can include:

Imipenem-cilastatin.
Ertapenem.
Doripenem where available.
Piperacillin-tazobactam.
Cefepime-based regimens.
Ceftazidime-avibactam or other newer agents for resistant organisms.

These products are not perfect substitutes. Meropenem retains value in severe hospital-acquired and complicated infections, particularly where broad Gram-negative coverage and central nervous system penetration are clinically relevant.

What generic entry risks exist?

Generic entry risk is high at the molecule level and moderate at the delivery-system level.

Main entry risks

Additional vial suppliers: Hospitals can substitute standard meropenem vials for the DUPLEX presentation.
Price competition: Generic injectable tenders often reward the lowest reliable supplier.
Shortage-driven entry: New manufacturers may enter when supply disruptions create attractive prices.
Contract loss: A single group purchasing or health-system contract can materially affect volume.
Container substitution: Competitors can use another dual-chamber or premixed technology.
Hospital preparation preferences: Some institutions may prefer vials because of lower acquisition cost.
Antimicrobial stewardship: Restricted-use policies can limit volume growth.

The strongest defense is consistent supply. Sterile injectable shortages can temporarily improve pricing and market share for reliable suppliers, but shortage-driven gains may reverse when capacity returns.

What are the manufacturing and intellectual-property barriers?

Manufacturing is more defensible than the molecule, but the barriers remain operational rather than absolute.

Critical manufacturing requirements

Sterile filling and lyophilization capability.
Validated container-closure systems.
Control of moisture and oxygen exposure.
Consistent meropenem potency and impurity profile.
Stability data for the combined product.
Validated activation and reconstitution performance.
Reliable sodium chloride filling.
Quality control for the dual-chamber package.
FDA-compliant documentation and change-control systems.

Meropenem is sensitive to degradation conditions, making stability and packaging important. A manufacturer must demonstrate that the product remains within specification throughout its labeled shelf life and after activation for the permitted administration period.

These requirements can slow entry and increase capital expenditure. They do not generally support monopoly pricing because the technology can be replicated by well-capitalized injectable manufacturers.

How does the DUPLEX product compare with meropenem vials?

Factor	DUPLEX container	Standard vial
Preparation	Reconstitution and dilution within the container	Requires separate diluent and preparation steps
Workflow	Can reduce handling steps	More labor-intensive
Acquisition cost	Often higher than basic vial supply	Usually lower
Medication-error potential	May reduce preparation complexity	More manipulation required
Storage	Requires specialized packaging and stability controls	Established vial infrastructure
Competitive differentiation	Moderate	Low
Hospital value proposition	Convenience and preparation efficiency	Cost and familiarity
Patent defensibility	Packaging and formulation claims	Minimal for mature generic product

The DUPLEX format has a stronger commercial proposition in high-volume hospitals, emergency settings, intensive-care units, and institutions seeking standardized preparation. Its value is weaker where pharmacy labor is available and procurement departments prioritize acquisition price.

What is the revenue exposure?

Product-specific revenue is generally not disclosed separately by manufacturers. The investment exposure must therefore be estimated through broader categories such as hospital injectables, generic pharmaceuticals, or contract sales.

Revenue sensitivity is usually determined by:

Meropenem market share.
Number of contracted hospitals.
Product strength and package size.
Average selling price.
Supply continuity.
Tender renewals.
Shortage conditions.
Manufacturing utilization.
Competitive launches.

A manufacturer with a diversified injectable portfolio can absorb meropenem price erosion more effectively than a company dependent on a narrow hospital-antibiotic range. The product is more valuable as part of a portfolio than as a standalone growth asset.

What could improve revenue?

Revenue could improve through:

New hospital contracts.
Competitor shortages.
Expanded premixed-product adoption.
Higher use of broad-spectrum antibiotics.
New strengths or package configurations.
Better fill rates.
Entry into additional geographic markets.

What could reduce revenue?

Revenue could decline through:

New generic suppliers.
Contract rebidding.
Lower hospital utilization.
Antimicrobial stewardship restrictions.
Price concessions.
Manufacturing interruptions.
Product recalls.
Substitution with other carbapenems or newer agents.

What is the likelihood of Paragraph IV litigation?

Paragraph IV risk is limited for the established meropenem molecule because the core patent period has ended. A Paragraph IV filing could still arise against a live patent directed to:

A specific DUPLEX formulation.
A dual-chamber container.
A stability profile.
A reconstitution process.
A manufacturing method.
A particular dosage presentation.

The likely litigation value of such patents is narrower than that of a compound patent. A generic challenger may avoid infringement by using a vial, changing the container architecture, altering the formulation, or pursuing a different manufacturing process.

What patent litigation affects the product?

The most relevant potential disputes would involve:

Infringement of packaging or container patents.
ANDA certification disputes.
Product-specific formulation claims.
Trade-secret claims involving manufacturing.
Contract disputes over hospital supply.
FDA manufacturing or quality enforcement.

The economic impact of litigation would depend on whether the challenged patent blocks only the DUPLEX presentation or also covers alternative meropenem products. A narrow packaging injunction would not necessarily remove meropenem from the market.

What is the biosimilar risk?

There is no biosimilar risk in the conventional sense. Meropenem is a small-molecule generic drug, not a biologic. Competition proceeds through abbreviated generic-drug pathways rather than biosimilar approval.

The relevant risk is generic substitution, not biosimilar interchangeability. Hospital formularies can choose among approved suppliers based on price, availability, quality history, and contract terms.

What licensing deals affect the product?

The product may involve licensing or supply arrangements relating to:

DUPLEX container technology.
Meropenem active pharmaceutical ingredient.
Contract manufacturing.
Regional commercialization rights.
Hospital group purchasing agreements.
Authorized generic distribution.

Licensing economics are likely to be more important for the delivery system and manufacturing platform than for meropenem itself. A license that grants access to a validated dual-chamber container can reduce development time and regulatory execution risk, but it may also create royalties, minimum-volume commitments, and dependence on the platform owner.

What geographic markets are most relevant?

The commercial opportunity is concentrated in regulated hospital markets with high use of sterile injectable antibiotics.

Geographic factor	Investment implication
United States	High regulatory and manufacturing standards; strong GPO and hospital contracting
Europe	National and regional tender pressure; varied reimbursement structures
Japan	Strict quality requirements and established hospital procurement channels
Emerging markets	Higher volume potential but greater price and regulatory variability
Government procurement markets	Large tenders with low margins and volume concentration

The DUPLEX format is most commercially relevant where pharmacy workflow, sterile preparation labor, and medication safety have measurable value. Price-sensitive markets may favor standard vials.

What generic launch scenarios should investors consider?

Base case

The product maintains recurring hospital demand, but pricing declines gradually as suppliers compete. Margin performance depends on manufacturing efficiency and contract retention.

Upside case

A competitor experiences a shortage or quality problem, allowing the DUPLEX supplier to gain temporary volume, improve fill rates, and secure new hospital contracts. Premixed adoption increases in high-acuity settings.

Downside case

A new supplier enters, hospital contracts are rebid at lower prices, or a manufacturing issue causes a recall or supply interruption. Customers shift to lower-cost vials or competing broad-spectrum antibiotics.

Scenario	Volume	Price	Margin	Main driver
Upside	Higher	Stable or higher	Expands	Competitor shortage and contract wins
Base case	Stable	Gradually lower	Stable to lower	Mature generic competition
Downside	Lower	Lower	Contracts	New entry, tender loss, or quality event

What is the investment conclusion?

Meropenem and Sodium Chloride in the DUPLEX container is a mature hospital-injectable product with recurring clinical demand and limited patent-driven upside. Its investment value depends on execution:

Reliable sterile manufacturing.
Competitive hospital pricing.
Strong distribution.
Retention of GPO and health-system contracts.
Low recall and shortage risk.
Efficient use of the DUPLEX platform.
Portfolio scale across other injectable products.

The product is unsuitable as a standalone thesis based on patent scarcity or exclusivity. It can support a defensive generic-injectables strategy when held by a manufacturer with manufacturing scale, a diversified hospital portfolio, and reliable supply performance.

Key Takeaways

Meropenem is an established generic carbapenem with no meaningful current composition-of-matter exclusivity.
The DUPLEX container provides workflow and preparation advantages rather than broad molecule-level protection.
Formulation, container, stability, and manufacturing patents may create narrower barriers.
Generic entry risk is high for meropenem vials and moderate for the specialized DUPLEX presentation.
The principal commercial risks are price erosion, hospital tender loss, supply interruption, and quality events.
There is no conventional biosimilar risk because meropenem is a small-molecule drug.
Revenue is likely to be material only as part of a broader hospital-injectable portfolio.
The strongest investment case is recurring demand plus manufacturing reliability, not patent exclusivity.

FAQs

Is Meropenem and Sodium Chloride in DUPLEX a branded drug?

It is generally positioned as a generic hospital injectable product, although the DUPLEX container can provide branded presentation and delivery-system differentiation.

Can hospitals substitute meropenem vials for the DUPLEX product?

Yes. Hospitals can generally use approved meropenem vial products when clinically and operationally appropriate, subject to formulary, pharmacy, and procurement policies.

Does the DUPLEX container justify a price premium?

It can justify a premium where reduced preparation steps, workflow efficiency, and medication-safety considerations have measurable value. Procurement departments may still favor lower-cost vial products.

Is meropenem exposed to antimicrobial-resistance risk?

Yes. Resistance can reduce effectiveness against certain organisms and influence prescribing protocols. At the same time, serious resistant infections can sustain demand for carbapenems in appropriate hospital settings.

What is the largest investment risk for this product?

The largest risk is loss of commercial value through generic price competition or supply disruption, rather than expiration of a core meropenem patent.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
Merck Sharp & Dohme LLC. (n.d.). Meropenem for injection prescribing information. U.S. Food and Drug Administration.
U.S. Food and Drug Administration. (n.d.). Generic drugs. FDA.
U.S. Food and Drug Administration. (n.d.). Drug shortages. FDA.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER